Results 131 to 140 of about 38,595 (290)

Multivariate adjusted odds ratios (95% confidence intervals) for initiating GLP-1 receptor agonists compared with initiators of non-GLP-1RA anti-diabetic drugs in type 2 diabetes patients of primary care in Germany.

, 2016
Multivariate adjusted odds ratios (95% confidence intervals) for initiating GLP-1 receptor agonists compared with initiators of non-GLP-1RA anti-diabetic drugs in type 2 diabetes patients of primary care in Germany.
Qing Qiao (439493), Karel Kostev (2577346), Susan Grandy (63301), Josh Hiller (2577343)   +3 more
core   +1 more source

Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub‐analysis of Hokkaido‐TZP study data

Journal of Diabetes Investigation, EarlyView.
Tirzepatide achieved significant HbA1c reduction in Japanese patients with type 2 diabetes without obesity, regardless of baseline BMI. Weight reduction was BMI‐dependent and enhanced by dietary consultations. No patient developed underweight status during the 6‐month observation period.
Tomoe Abe, Fumika Maruyama, Eisuke Nishikawa, Miki Ito, Yukie Miyano, Hiroki Yamagata, Taiga Sasaki, Hidemitsu Sakagami, Akinobu Nakamura, Hiroshi Nomoto, on behalf of the Hokkaido‐TZP Study Group   +10 more
wiley   +1 more source

Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real‐world observational study

Journal of Diabetes Investigation, EarlyView.
This real‐world observational study enrolled 256 patients with type 2 diabetes and chronic kidney disease (T2D‐CKD). After 12 months of finerenone treatment, 45 patients completed follow‐up. Finerenone was associated with significant improvements in insulin resistance markers (HOMA‐IR, TyG index), lipid profile (LDL‐C), glycemic control (HbA1c), and ...
Xin Zhao, Bohan Liu, Ran Sun, Yaxuan Shi, Ya Liu   +4 more
wiley   +1 more source

Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management

Molecular Metabolism
Type 2 diabetes and obesity impact billions of people and the global prevalence is only growing. Current treatment options, which include pharmacotherapy, e.g., GLP-1 receptor agonists (GLP-1RA) and bariatric surgical approaches have limitations. GLY-200
Taylor L. Carlson, Mark Fineman, Stace Kernodle, Chelsea R. Hutch, Christine Bryant, Kevin Colbert, Randy J. Seeley, Ashish Nimgaonkar   +7 more
doaj   +1 more source

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

Journal of Internal Medicine, EarlyView.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt   +2 more
wiley   +1 more source

GLP-1’s role in neuroprotection: a systematic review

, 2019
Glucagon-like peptide 1 (GLP-1) is a target for treatment of diabetes; however, its function in the brain is not well studied. In this systematic review, we aimed to analyze the neuroprotective role of GLP-1 and its defined mechanisms.
Ihsan Solaroğlu (6540053), Damla Erbil (6540041), Candan Yasemin Eren (6540044), Cağrı Demirel (6540047), Mehmet Utku Küçüker (6540050), Hale Yapıcı Eser (6540056)   +5 more
core   +1 more source

A Systematic Review and Meta‐Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition

Obesity Reviews, EarlyView.
ABSTRACT Background In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Amene Saghazadeh, Mahsa Dolatshahi, Soheil Mohammadi, Sara Hosseinzadeh Kassani, Mahshid Naghashzadeh, Joseph E. Ippolito, Claude B. Sirlin, Bettina Mittendorfer, Matthew R. Brier, Suzanne E. Schindler, John C. Morris, Danny Mou, Hani Charles Soudah, Tammie L. S. Benzinger, Cyrus A. Raji   +14 more
wiley   +1 more source

Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status

Importance: non-alcoholic fatty liver disease (NAFLD) is a cardiovascular risk factor, but whether sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) reduce cardiovascular risk in T2D patients with
Lee, Bon Hyang, Shin, Ju-Young, Jeong, Han Eol, Byrne, Chris, Bea, Sungho, Filion, Kristian B., Cho, Young Min, Chang, Yoosoo, Yu, Oriana HY   +8 more
core   +1 more source

GLP-1R immunofluorescence in DRG neurons.

, 2018
Cultured adult rat DRG neurons (A, B, C) showing β tubulin immunofluorescence (green in A), GLP-1R expression (red in B), and the merged image (C). Bar = 200 μm.
Mike Fox (5309444), Marco Sinisi (56682), Ayesha Akbar (4918297), Anthony MacQuillan (5309447), Ben Jones (554472), Tom Quick (5309438), Praveen Anand (42856), Steve R. Bloom (5309441), Uma Anand (1418002), Yuri E. Korchev (1298694), Yiangos Yiangou (61513)   +10 more
core   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source